annexin A3

Home
Ligands
annexin A3 (Human)

GtoPdb Ligand ID: 13777

Synonyms: annexin III | calcimedin 35-alpha | inositol 1,2-cyclic phosphate 2-phosphohydrolase (EC 3.1.4.43) | lipocortin III | placental anticoagulant protein III

Compound class: Endogenous peptide in human, mouse or rat

Comment: Annexin A3 (ANXA3) is one member of a family of intracellular calcium-dependent phospholipid-binding proteins (13 genes in humans). It regulates cellular growth and signal transduction pathways via inhibition of phopholipase A2. This activity modulates the conversion of inositol 1,2-cyclic phosphate to inositol 1-phosphate.
Pathogenic effects of ANXA3 have been reported in the development of cancers [2,4], in particular triple-negative breast cancer (TNBC) [5]. Pharmacological modulation of ANXA3 is therefore of interest for the development of TNBC therapeutics.

Species: Human

References
1. Liang Y, Min D, Fan H, Liu K, Tu J, He X, Liu B, Zhou L, Liu S, Sun X. (2023) Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer. Acta Pharm Sin B, 13 (4): 1686-1698. [PMID:37139408]
2. Liu C, Li N, Liu G, Feng X. (2021) Annexin A3 and cancer. Oncol Lett, 22 (6): 834. [PMID:34712358]
3. Liu K, Zhu C, Liang Y, Min D, Jin Z, Sun X. (2025) Discovery of a Novel 1,4-Benzodiazepine Derivative as a Highly Selective ANXA3 Degrader for the Treatment of Triple-Negative Breast Cancer. J Med Chem, 68 (5): 5358-5381. [PMID:40013713]
4. Wu N, Liu S, Guo C, Hou Z, Sun MZ. (2013) The role of annexin A3 playing in cancers. Clin Transl Oncol, 15 (2): 106-10. [PMID:23011854]
5. Zhou T, Li Y, Yang L, Tang T, Zhang L, Shi J. (2017) Annexin A3 as a Prognostic Biomarker for Breast Cancer: A Retrospective Study. Biomed Res Int, 2017: 2603685. [PMID:28497041]

References

1. Liang Y, Min D, Fan H, Liu K, Tu J, He X, Liu B, Zhou L, Liu S, Sun X. (2023)
Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer.
Acta Pharm Sin B, 13 (4): 1686-1698. [PMID:37139408]

2. Liu C, Li N, Liu G, Feng X. (2021)
Annexin A3 and cancer.
Oncol Lett, 22 (6): 834. [PMID:34712358]

3. Liu K, Zhu C, Liang Y, Min D, Jin Z, Sun X. (2025)
Discovery of a Novel 1,4-Benzodiazepine Derivative as a Highly Selective ANXA3 Degrader for the Treatment of Triple-Negative Breast Cancer.
J Med Chem, 68 (5): 5358-5381. [PMID:40013713]

4. Wu N, Liu S, Guo C, Hou Z, Sun MZ. (2013)
The role of annexin A3 playing in cancers.
Clin Transl Oncol, 15 (2): 106-10. [PMID:23011854]

5. Zhou T, Li Y, Yang L, Tang T, Zhang L, Shi J. (2017)
Annexin A3 as a Prognostic Biomarker for Breast Cancer: A Retrospective Study.
Biomed Res Int, 2017: 2603685. [PMID:28497041]